[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]

Full Abstract

Recently, some new anticancer agents and hormonal agents can be used to treat breast cancer, and more patients are administering combinations of these drugs in clinical practice. Tegafur and Uracil (UFT) have been widely used for the postoperative chemotherapy of breast cancer, and often combined with hormonal agents. However, due consideration has not been given to safety and compliance of the combined use of UFT and aromatase inhibitor (AI). We therefore studied the safety and compliance with UFT alone and in combination with the hormonal agents tamoxifen or anastrozole as postoperative therapy in postmenopausal women with breast cancer. Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored. Combined therapy was not associated with a significant increase in the incidence of adverse events or a decrease in compliance, even in older adult patients. Therefore, we consider UFT plus a hormonal agent (especially anastrozole) to be a treatment option for patients with HER2-negative highly or incompletely endocrine responsive disease who require relatively moderate chemotherapy or for older adult patients who require treatment with low toxicity.

Author information

Author/s: Taguchi, Tetsuya (T); Noguchi, Shinzaburo (S);

Affiliation: Dept. of Surgical Oncology, Osaka University Medical School.

Journal and publication information

Publication Type: Clinical Trial; English Abstract; Journal Article; Multicenter Study

Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho), published in Japan. (Language: jpn)

Reference: 2009-Sep; vol 36 (issue 9) : pp 1465-74

Dates: Created 2009/09/16; Completed 2009/10/22;

PMID: 19755814, status: MEDLINE (last retrieval date: 10/22/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Middle Aged
Nitriles - administration & dosage; adverse effects
Patient Compliance
Postmenopause
Tamoxifen - administration & dosage; adverse effects
Tegafur - administration & dosage; adverse effects; therapeutic use
Triazoles - administration & dosage; adverse effects
Uracil - administration & dosage; adverse effects; therapeutic use

Associated Chemicals: Antineoplastic Agents, Hormonal (0) ; Nitriles (0) ; Triazoles (0) ; Tamoxifen (10540-29-1) ; anastrozole (120511-73-1) ; Tegafur (17902-23-7) ; Uracil (66-22-8) ; 1-UFT protocol (74578-38-4)

These are the highest related articles currently in the database: